Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01386216 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Bone Marrow Cell Concentrate Prepared Using the Magellan System to Treat Critical Limb Ischemia (CLI)
A Phase 1 study, sponsored by Arteriocyte.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01386216 is a Phase 1 study that has completed, run by Arteriocyte. The registered enrollment target is 18 participants.
The verdict
NCT01386216, a Phase 1 study, has completed, sponsored by Arteriocyte.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of administration of marrow-derived autologous hematopoietic stem cells (HSC) concentrate and platelet-rich plasma (PRP) gel for the treatment of Critical Limb Ischemia (CLI).
Interventions
- DEVICE Magellan®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-04 |
| Est. Completion | 2016-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01386216
The ClinicalTrials.gov registry entry for NCT01386216 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arteriocyte, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Magellan® is the first listed.
NCT01386216 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01386216 about?
NCT01386216 is a clinical study titled "Safety Study of Bone Marrow Cell Concentrate Prepared Using the Magellan System to Treat Critical Limb Ischemia (CLI)". The purpose of this study is to evaluate the safety of administration of marrow-derived autologous hematopoietic stem cells (HSC) concentrate and platelet-rich plasma (PRP) gel for the treatment of Critical Limb Ischemia (CLI).
What is the current status of trial NCT01386216?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2011-04. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01386216?
The interventions under investigation include: Magellan® (DEVICE).
Who is sponsoring clinical trial NCT01386216?
This trial is sponsored by Arteriocyte, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.